2,056 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by Dupont Capital Management Corp

Dupont Capital Management Corp purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,056 shares of the company’s stock, valued at approximately $185,000.

Other large investors have also bought and sold shares of the company. DekaBank Deutsche Girozentrale raised its position in Neurocrine Biosciences by 48.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 107,211 shares of the company’s stock worth $8,834,000 after purchasing an additional 35,131 shares in the last quarter. Holocene Advisors LP acquired a new position in Neurocrine Biosciences in the second quarter worth about $14,828,000. Rockefeller Capital Management L.P. raised its position in Neurocrine Biosciences by 62.1% in the second quarter. Rockefeller Capital Management L.P. now owns 364,771 shares of the company’s stock worth $30,798,000 after purchasing an additional 139,794 shares in the last quarter. NEXT Financial Group Inc raised its position in Neurocrine Biosciences by 89.8% in the second quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock worth $47,000 after purchasing an additional 265 shares in the last quarter. Finally, GAM Holding AG raised its position in Neurocrine Biosciences by 10.1% in the second quarter. GAM Holding AG now owns 88,507 shares of the company’s stock worth $7,473,000 after purchasing an additional 8,100 shares in the last quarter. 96.07% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Gary A. Lyons sold 5,000 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $100.22, for a total transaction of $501,100.00. Following the sale, the director now directly owns 230,697 shares in the company, valued at $23,120,453.34. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dimitri E. Grigoriadis sold 10,188 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $100.34, for a total transaction of $1,022,263.92. Following the sale, the insider now owns 118,596 shares in the company, valued at $11,899,922.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,795 shares of company stock worth $3,681,988. Company insiders own 4.30% of the company’s stock.

Shares of Neurocrine Biosciences stock opened at $110.77 on Friday. The firm’s 50-day moving average price is $95.60 and its two-hundred day moving average price is $89.48. The company has a current ratio of 7.08, a quick ratio of 7.32 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $9.43 billion, a price-to-earnings ratio of 503.50, a P/E/G ratio of 6.41 and a beta of 1.20. Neurocrine Biosciences, Inc. has a 1-year low of $64.72 and a 1-year high of $111.08.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 4th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.07). The firm had revenue of $222.09 million during the quarter, compared to analyst estimates of $211.31 million. Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The company’s revenue for the quarter was up 46.3% on a year-over-year basis. During the same quarter last year, the business posted $0.52 earnings per share. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 0.82 EPS for the current year.

NBIX has been the subject of several recent research reports. Credit Suisse Group increased their price target on shares of Neurocrine Biosciences from $95.00 to $110.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Wednesday, July 31st. Royal Bank of Canada set a $118.00 price objective on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Friday, September 6th. CIBC started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, July 16th. They set an “outperform” rating and a $100.00 price objective on the stock. Finally, Piper Jaffray Companies upped their price objective on shares of Neurocrine Biosciences from $111.00 to $116.00 in a research note on Tuesday, November 5th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $106.94.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Article: What are some reasons analysts would give stocks a buy rating?

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.